RxDoctor Payments Data

Francisco Reytor, MD

General Practice · Miami, FLNPI 1295714376

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 62 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$554
  • GSK$146
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$77
  • Johnson & Johnson$68
  • Amgen$64
  • Kowa Pharmaceuticals America, Inc.$58
  • plus $347 from 11 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,314 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$101,501
Medicare patients
96
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$127,981
LinzessLinaclotide115$77,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$58,031
JardianceEmpagliflozin48$42,919
JanuviaSitagliptin Phosphate32$40,537
OzempicSemaglutide37$37,306
JanumetSitagliptin Phos/Metformin Hcl36$36,403
EntrestoSacubitril/Valsartan48$33,063
XareltoRivaroxaban29$27,086
TrulicityDulaglutide24$23,039
FarxigaDapagliflozin Propanediol30$20,910
Ondansetron Hcl74$10,730
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$9,339
VascepaIcosapent Ethyl17$8,373
Breo ElliptaFluticasone/Vilanterol22$8,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$127,981200 claims
AbbVieLinzess$34$77,053115 claims
GSKTrelegy Ellipta, Breo Ellipta$146$66,065108 claims
Novo NordiskOzempic$23$37,30637 claims
Johnson & JohnsonXarelto, Invokamet$68$33,56440 claims
NovartisEntresto$40$33,06348 claims
AstraZenecaFarxiga$554$20,91030 claims
Sanofi-aventis U.S. LLCLantus$15$4,72944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →